...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>International clinical psychopharmacology >Prognostic indicators for early discontinuation of risperidone long-acting injection.
【24h】

Prognostic indicators for early discontinuation of risperidone long-acting injection.

机译：利培酮长效注射剂的早期停用的预后指标。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Although efficacy trials have been conducted on risperidone long-acting injection (RLAI), its most appropriate utilization in clinical practice remains unclear. This 6-month, follow-up study investigated prognostic indicators for early discontinuation of RLAI. Consecutive sampling was conducted for adult patients with a psychotic disorder commenced on RLAI, whose injection was dispensed by one of three South London psychiatric hospital pharmacies. Prescription data were collected prospectively and clinical data retrospectively. Eightly-one out of 88 (92.0%) eligible patients were included, of whom 29 (35.8%) had treatment refractoriness and 30 (37.0%) discontinued within 6 months. Patients with a preceding oral antipsychotic were more likely to discontinue RLAI than those with a preceding depot; treatment refractoriness weakly confounded this relationship [summary adjusted odds ratio (OR) 2.68, 95% confidence interval (CI) 0.95-7.53, P=0.061]. After adjusting for preceding antipsychotic type, patients with treatment refractoriness were no more likely to discontinue than those without (summary adjusted OR 1.55, 95% CI 0.59-4.11, P=0.376). Sociodemographic factors and other clinical factors were non-predictive of discontinuation. For this first wave of patients commenced on RLAI, many had treatment refractoriness. RLAI discontinuation is high early on but subsequently tapers off. Preceding antipsychotic type (depot versus oral) is a stronger prognostic indicator than treatment refractoriness for RLAI discontinuation.
机译：尽管已对利培酮长效注射剂（RLAI）进行了功效试验，但尚不清楚其在临床实践中最合适的利用。这项为期6个月的随访研究调查了RLAI早期停用的预后指标。从RLAI开始对患有精神病的成年患者进行连续采样，RLAI的注射由南伦敦的三家精神病医院药房之一分配。前瞻性收集处方数据，回顾性收集临床数据。在88名合格患者中占八分之一（92.0％），其中29名（35.8％）患有难治性治疗，其中30名（37.0％）在6个月内停药。既往有口服抗精神病药的患者比有既往仓库的患者更有可能停用RLAI。治疗难治性弱化了这种关系[总调整比值比（OR）2.68，95％置信区间（CI）0.95-7.53，P = 0.061]。在对先前的抗精神病药类型进行调整后，具有治疗难治性的患者与没有接受抗精神病药的患者相比，停药的可能性不大（汇总调整为OR 1.55，95％CI 0.59-4.11，P = 0.376）。社会人口统计学因素和其他临床因素不能预测停药的发生。由于第一波患者开始接受RLAI治疗，许多患者出现了治疗难治性。 RLAI的停用从一开始就很高，但随后逐渐减少。相对于RLAI终止治疗的难治性，先前的抗精神病药物类型（储库或口服）是更强的预后指标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号